CD Biosynsis offers comprehensive Mammalian Cells Genome Editing Services, utilizing a full suite of precision tools to modify various mammalian cell hosts for applications ranging from therapeutic protein production to advanced disease modeling. Mammalian cells, including CHO (Chinese Hamster Ovary) cells, HEK293 cells, and various primary/immortalized cell lines, are essential for producing complex biotherapeutics like monoclonal antibodies (mAbs) and for developing gene/cell therapies. Our services provide access to advanced CRISPR-based technologies, including CRISPR-Cas9 for stable integration and multi-allelic deletion, Base Editing for single-nucleotide precision, and CRISPRi for tunable gene repression. We specialize in providing highly efficient, stable, and verifiable modifications that accelerate the optimization of cell lines for enhanced titer, improved product quality (e.g., glycosylation), and robust bioprocessing performance or functional studies.
Get a QuoteEffective strain engineering in mammalian cells requires precise control over gene function—from permanent elimination (e.g., proteases, pro-apoptotic genes) to subtle tuning (e.g., metabolic enzymes). Our integrated Genome Editing platform provides all necessary tools to achieve these goals, leveraging optimized delivery systems (RNP, Lentivirus) and specialized gRNAs tailored for complex eukaryotic genomes. This ensures accurate manipulation, including stable integration into genomic safe harbor loci and precise control over metabolic and glycosylation pathways. This foundational capability is crucial for both commercial cell line development and for creating advanced in vitro disease models.
Standard editing platform for targeted DNA double-strand breaks (DSBs), optimized for efficient transformation and utilizing both HDR (for KI) and NHEJ (for KO) pathways.
DSB-free system for highly efficient, clean single-nucleotide conversions (C>T or A>G), ideal for promoter/UTR tuning and optimizing enzyme activity.
Tunable and reversible gene knockdown (repression) for rapidly optimizing the expression balance of metabolic pathways or host factors without permanent edits.
Permanent, multi-allelic deletion or disruption of target genes (e.g., proteases, pro-apoptotic genes) via NHEJ to enhance cell fitness and product stability.
Accurate integration of large expression cassettes (e.g., mAbs or reporter genes) into genomic safe harbor loci via HDR for stable, high-level expression.
Simultaneous targeting of multiple genes or alleles using gRNA arrays to accelerate the construction of complex, optimized production cell lines.
Stable integration of antibody expression cassettes into highly expressed loci and enhancement of anti-apoptosis pathways to maximize the specific productivity (Qp).
Editing glycosylation genes (KO/KI) to control the glycan profile, achieving desired homogeneity and human-like quality for therapeutic proteins.
Integrated HTS and editing to accelerate the creation of highly controlled, matched pairs for functional genomic studies and large-scale manufacturing clones.
A systematic process for rational design, precise editing, and stable clone isolation.
1. Rational Design & System Preparation
2. Transfection & Editing
3. Clone Isolation & Screening
4. Verification & Stable Cell Line Delivery
Identify all necessary genomic modifications (KO, KI, tuning). Design gRNAs for high on-target specificity.
Prepare the Cas9/BE/CRISPRi system (RNP/Lentivirus/Plasmid) optimized for the specific mammalian host (e.g., CHO, HEK293).
Design HDR repair templates (donor DNA) with necessary homology arms for Gene Knock-in.
Deliver the editing components into the host cell line via optimized protocols (Electroporation or Transfection).
Culture cells to allow the repair mechanisms (NHEJ or HDR) to finalize the genomic edit.
Apply antibiotic selection or FACS sorting to enrich for edited clones.
Genotype verification via junction PCR and definitive sequencing of the edited locus to confirm clean edit.
Phenotypic validation of the final clone for stable expression and product functionality.
Delivery of the verified Master Cell Bank (MCB) or research cell line and comprehensive documentation.
Targeted Bioproduction Hosts
Expertise in engineering industry-standard hosts like CHO and HEK293, focusing on optimization for stable, high-titer production of complex biotherapeutics.
Precision Glycoengineering
CRISPR-based editing of glycosylation pathways (KO/KI) ensures precise control over the N-glycan profile, achieving human-like quality essential for therapeutic efficacy.
Stable Genomic Integration
Preference for CRISPR/HDR-mediated knock-in into verified genomic safe harbor loci guarantees consistent, high-level expression and avoids the instability of random integration.
Full CRISPR Toolset
Access to Cas9, Base Editing, and CRISPRi ensures the most appropriate tool is selected for any modification, from large deletions to subtle promoter tuning.
1. Which mammalian cell lines do you support for editing?
We support all major bioproduction and research lines, including CHO (CHO-K1, DG44, GS), HEK293 (HEK293T, HEK293-F), various hybridomas, and specific primary cell lines for research (e.g., iPSCs).
2. What is the role of Base Editing in optimizing mammalian cells?
Base Editing is used for subtle, precise modifications, such as fine-tuning promoter strengths, optimizing UTRs for enhanced mRNA stability, or introducing specific point mutations for functional studies, all without creating a DNA double-strand break.
3. How do you ensure the stability of the final engineered cell line?
Stability is primarily ensured by using CRISPR/HDR to integrate the therapeutic gene or modification into verified genomic safe harbor loci, avoiding unstable random integration that leads to gene silencing.
4. Can you perform multiplex editing in mammalian cells?
Yes. We use multiplex gRNA systems and RNP delivery to simultaneously target and disrupt or modify multiple genes (e.g., knocking out multiple proteases or pro-apoptotic genes) to accelerate complex chassis development.
5. What is the biggest challenge in editing CHO cells compared to HEK293 cells?
CHO cells present a challenge due to their pseudo-tetraploid genome and genetic heterogeneity, making it difficult to achieve multi-allelic disruption (KO). HEK293 cells are generally easier to transfect and edit but are less commonly used for commercial mAb production.
6. What delivery systems are used for the CRISPR components?
We use optimized systems based on the project: RNP (Ribonucleoprotein) for transient, high-efficiency edits; plasmid for stable selection; and Lentivirus for stable integration in hard-to-transfect cell lines.
7. How is the final monoclonal cell line verified?
Verification includes single-cell cloning (FACS/ClonePix), junction PCR/sequencing to confirm genotype (KI), TIDE/Sanger sequencing (KO), and phenotypic analysis (titer, viability) to confirm the desired trait.
8. What is the primary role of CRISPRi in mammalian bioproduction?
CRISPRi is used for tunable repression (knockdown) of genes, which is ideal for balancing metabolic flux (e.g., reducing lactate production) or managing the expression of essential genes that might be lethal if completely knocked out.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.